


07-19-04

ifw



Express Mail No.: EV475140872US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Muller et al.	Confirmation No.:	To Be Assigned
Serial No.:	10/748,085	Group Art Unit:	1614
Filed:	December 29, 2003	Examiner:	To Be Assigned
For:	FLUOROALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES	Attorney Docket No.:	9516-084-999

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97 & §1.56

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent and Trademark Office of all references coming to the attention of Applicant or his attorneys which are or may be related to patentability of the claimed invention, Applicant hereby directs the Examiner's attention to references **B01** to **B06** and **C01** to **C36**, which are listed on the accompanying revised PTO Form 1449.


Legible copies of listed references **B01** to **B06** and **C01** to **C36** are provided herewith. Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application. Identification of the listed references is not to be construed an admission by Applicant or his attorneys that such references are available as "prior art" against the subject application.

Pursuant to 37 C.F.R. § 1.97(b), it is estimated that no fee is due. However, if a fee is deemed to be due, please charge the required fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: July 15, 2004


  
Anthony M. Insogna 35,203  
(Reg. No.)  
**JONES DAY**  
12750 High Bluff Drive, Suite 300  
San Diego, California 92130  
(858) 314-1200


By:   
Nicholas J. DiCeglie, Jr. 51,615  
(Reg. No.)  
**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, New York 10017-6702  
(212) 326-3939

Pursuant to 37 C.F.R. § 1.97(b), it is estimated that no fee is due. However, if a fee is deemed to be due, please charge the required fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: July 15, 2004

  
\_\_\_\_\_  
Anthony M. Insogna 35,203  
(Reg. No.)  
**JONES DAY**  
12750 High Bluff Drive, Suite 300  
San Diego, California 92130  
(858) 314-1200

By:   
\_\_\_\_\_  
Nicholas J. DiCeglie, Jr. 51,615  
(Reg. No.)  
**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, New York 10017-6702  
(212) 326-3939

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

9516-084-999

APPLICATION NO

10/748,085

APPLICANT

Muller et al.

FILING DATE

12/29/03

GROUP

1614

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
B01	WO 02/16305	2/28/02	PCT			
B02	WO 01/90076	11/29/01	PCT			
B03	WO 01/34606	5/17/01	PCT			
B04	WO 01/34603	5/17/01	PCT			
B05	WO 97/23457	7/3/97	PCT			
B06	DD 298 389	10/27/83	East Germany			

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Baughman et al., 1990, "Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis," J. Lab. Clin. Med. 115(1): 36-42
C02	Beavo et al., 1990, "Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors," Trends Pharmacol. Sci. 11(4): 150-155
C03	Beckett et al., 1996, Drug Discovery Today 1:16-26
C04	Berge et al., 1977, "Pharmaceutical salts," J. Pharm. Sci. 66(1): 1-19
C05	Bertolini et al., 1986, "Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors," Nature 319(6053): 516-518
C06	Bissonnette et al., 1989, "Pulmonary inflammation and fibrosis in a murine model of asbestosis and silicosis. Possible role of tumor necrosis factor," Inflammation 13(3): 329-339
C07	Clouse et al., 1989, "Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone," J. Immunol. 142(2): 431-438
C08	Dezube et al., 1990, "Pentoxifylline and wellbeing in patients with cancer," Lancet 335(8690):662
C09	Duh et al., 1989, "Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat," Proc. Natl. Acad. Sci. USA 86(15): 5974-5978
C10	Elliott et al., 1995, "TNF alpha blockade in rheumatoid arthritis: rationale, clinical outcomes and mechanisms of action," Int. J. Immunopharmacol. 17(2): 141-145
C11	Ferrai-Baliviera et al., 1989, "Tumor necrosis factor induces adult respiratory distress syndrome in rats," Arch. Surg. 124(12): 1400-1405
C12	Folks et al., 1989, "Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone," Proc. Natl. Acad. Sci. USA 86(7): 2365-2368
C13	Grau et al., 1989, "Tumor necrosis factor and disease severity in children with falciparum malaria," N. Engl. J. Med. 320(24):1586-91
C14	Grewe et al., 1982, "Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness," J. Allergy Clin. Immunol. 70(6): 452-457

C15	Guay et al., 2002, "Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor," Bioorg. Med. Chem. Lett. 12(11): 1457-1461
C16	Hanifin et al., 1996, "Type 4 Phosphodiesterase Inhibitors Have Clinical and in vitro Anti-inflammatory Effects in Atopic Dermatitis," J. of Investigative Dermatology 107(1):51-56
C17	Hatzelmann et al., 2001, "Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro," J. Pharmacol. Exp. Ther. 297(1):267-279
C18	Hinshaw et al., 1990, "Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha)," Circ. Shock 30(3):279-292
C19	Holler et al., 1990, "Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation," Blood 75(4): 1011-1016
C20	Houslay et al., 1998, "The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions," Adv. Pharmacol. 44:225-342
C21	Huang et al., 2001, "The Next Generation of PDE4 inhibitors," Curr. Opin. Chem. Biol. 5:432-438
C22	Johnson et al., 1989, "Tumors producing human tumor necrosis factor induced hypercalcemia and osteoclastic bone resorption in nude mice," Endocrinology 124(3):1424-1427
C23	List et al., 1990, "The myelodysplastic syndromes: biology and implications for management," J. Clin. Oncol. 8(8):1424-1441
C24	Lowe et al., 1992, Drugs of the Future 17(9):799-807
C25	Millar et al., 1989, "Tumour necrosis factor in bronchopulmonary secretions of patients with adult respiratory distress syndrome," Lancet 2(8665):712-714
C26	Monte et al., 1990, "Productive human immunodeficiency virus-1 infection of megakaryocytic cells is enhanced by tumor necrosis factor-alpha," Blood 79(10): 2670-2679
C27	Piguet et al., 1990, "Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis," Nature 344(6263):245-247
C28	Poli et al., 1990, "Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression," Proc. Natl. Acad. Sci. USA 87(2): 782-785
C29	Poli et al., 1992, "The effect of cytokines and pharmacologic agents on chronic HIV infection," AIDS Res. Hum. Retroviruses 8(2):191-197
C30	Rice et al., 1989, "An inducible endothelial cell surface glycoprotein mediates melanoma adhesion," Science 246(4935):1303-1306
C31	Shealy et al., 1968, "Synthesis of D- and L-thalidomide and related studies," J. Pharm. Sci. 57(5):757-764
C32	Shealy et al., 1965, "D- and L-thalidomide," Chem. Ind. 24:1030-1031
C33	Tierney et al., ed., 1998, Curr. Med. Diag. Treat. 37th ed., 499
C34	Tracey et al., 1987, "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia," Nature 330(6149):662-664
C35	Verghese et al., 1995, "Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors," J. Pharmacol. Exp. Ther. 272(3): 1313-1320
C36	Van Dulleman et al., 1995, "Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)," Gastroenterology 109(1):129-135

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.